Is Prostate Specific Antigen Velocity Selective For Clinically Significant Prostate Cancer In Screening?
UroToday.com – With the knowledge that screening for prostate cancer will lead to over detection and subsequent over treatment, the call for tests discriminating between non aggressive and aggressive prostate cancer is growing. If pre-biopsy data could make this distinction, a lot of unnecessary biopsies would be spared. The amount of prostate cancer specific antigen (PSA) increase in a year, PSA velocity (PSAV), has been suggested as a factor predictive for aggressive disease. Therefore, PSAV was calculated in a large, population-based screening cohort (n=2217) and its predictive value on aggressive prostate cancer was assessed. It is important to note that each screening subject was biopsied at the time of the last PSA determination. Therefore, the presence or absence for each individual was known and the attribution bias was brought to a minimum. Although PSAV was predictive of aggressive disease when assessed as a single variable, this predictive value was lost when more clinical d
